Pediatrik Nöroloji Hastalarında Bireysel Tedavi
Özet
Tıp dünyası, hassas tıp kavramı çerçevesinde reaktif bir yapıdan daha proaktif ve bireyselleştirilmiş tedavi modellerine doğru evrilmektedir. Çocuk nörolojisinde, özellikle genetik epilepsi vakalarında, hastalıkların moleküler temelinin anlaşılması hedefe yönelik ve daha etkili tedavi stratejilerinin geliştirilmesine olanak tanımaktadır. Klinik heterojenite ve tanı zorlukları gibi engellere rağmen, genetik ve omik verilerin klinik bilgilerle entegrasyonu, hastaların doğru tedaviye yönlendirilmesinde kritik bir rol oynamaktadır. Gelecekte, yapay zeka destekli büyük veri analizi ve sistem biyolojisi yaklaşımları, nörolojik hastalıkların yönetiminde başarıyı önemli ölçüde artırma potansiyeline sahiptir.
The medical field is shifting from a reactive approach to a proactive model based on precision medicine, which emphasizes predictive, personalized, preventive, and participatory care. In pediatric neurology, particularly regarding genetic epilepsy, understanding the molecular basis of disorders is enabling the development of more effective, targeted treatment strategies. Despite challenges like clinical heterogeneity and diagnostic difficulties, integrating genetic and omics data with clinical records plays a critical role in guiding patient care. In the future, artificial intelligence-driven big data analysis and systems biology approaches hold the potential to significantly improve treatment outcomes in neurological disease management.
Referanslar
Flores, M, Glusman, G, Brogaard, K, Price, Nathan D; Hood, L. P4 medicine: how systems medicine will transform the healthcare sector and society. Personalized Medicine 2013; 10 (6): 565–576. doi:10.2217/PME.13.57. PMC 4204402. PMID 25342952
Geoffrey SG, Phillips KA. Precision Medicine: From Science to Value. Health Aff (Millwood) 2018; 37(5): 694–701. doi: 10.1377/hlthaff.2017.1624.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/personalized-medicine
Jain KK. Personalized medicine. Curr Opin Mol Ther 2002; 4: 548–58
https://obamawhitehouse.archives.gov/precision-medicine
Cohrs RJ, Parviz TM, Bidant GL, Higgins PJ, Shahzad A. Translational Medicine definition by the European Society for Translational Medicine. New Horizons in Translational Medicine, 2015; 2(3): 86-88
Collins F.S. The human genome project and the future of medicine. Ann. N Acad Sci 1999; 882: 42–55
Gibbs RM, Lipnick S, Bateman JW, et al. Toward Precision Medicine for Neurological and Neuropsychiatric Disorders. Cell Stem Cell 2018; 23(1): 21-24
Speed D, O’Brien TJ, Palotie A, et al. Describing the genetic architecture of epilepsy through heritability analysis. Brain 2014; (137(10): 2680-2689 doi:10.1093/brain/awu206
Chen T, Giri M, Xia Z, et al. Genetic and epigenetic mechanisms of epilepsy: a review. Neuropsychiatric Disease and Treatment 2017; 13: 1841-1859
https://www.epilepsydiagnosis.org/aetiology/gene-abnormalities-overview.html
Guerrini R, Noebels J. How can advances in epilepsy genetics lead to better treatments and cures? Adv Exp Med Biol 2014; 813: 309-317 doi: 10.1007/978-94-017-8914-1_25
Pearl PL. Amenable Treatable Severe Pediatric Epilepsies. Semin Pediatr Neuro 2016, l23:158-166
Smith LA, Ullmann JFP, Olson HE, et al. A Model Program for Translational Medicine in Epilepsy Genetics. Journal of Child Neurology 2017:32(4);429-436
Soo AKS, Ferrini A, Kurian MA. Precision medicine for genetic childhood movement disorders. Dev Med Child Neurol. 2021 Mar 24. doi: 10.1111/dmcn.14869. Online ahead of print.
Leu C, Stevelink R, Smith AW, et al. Polygenic burden in focal and generalized epilepsies. Brain 2019; 142: 3473– 3481
Parker WE, Orlova KA, Parker WH, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med 2013; 5(182):182ra53. doi: 10.1126/scitranslmed.3005271
Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm 2020; 7: e730
Mueller SH, Färber A, Prüss H, et al. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. Ann Neurol 2018; 83: 863– 869
Chung W-H, Hung S-I, Hong H-S, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428(6982): 486. doi: 10.1038/428486a
McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134– 43.
Noelle SB, Delanty EN. Precision therapy in the genetic epilepsies of childhood. Dev Med Child Neurol. 2021: 4. doi: 10.1111/dmcn.14929
Han Z, Chen C, Christiansen A, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med 2020; 12: eaaz6100
Colasante G, Lignani G, Brusco S, et al. Cas9-Based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice. Mol Ther 2019; 28: 235– 53
Raikwar SP, Kikkeri NS, Sakuru R, et al. Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders. Journal of Neuroimmune Pharmacology 2019; 14:608–641
Cho MJ, Kwon SS, Ko A, et al. Efficacy of stiripentol in Dravet syndrome with or without SCN1A mutations. J Clin Neurol 2018; 14: 22– 8
Mullen SA, Carney PW, Roten A, et al. Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine. Neurology 2018; 90: e67– 72.
Tărlungeanu DC, Novarino G. Genomics in neurodevelopmental disorders: an avenue to personalized medicine. Experimental & molecular medicine 2018; 50(8): 1-7
Strafella C, Caputo V, Galota MR, et al. Application of Precision Medicine in Neurodegenerative Diseases. Front Neurol 2018; 23(9):701 doi: 10.3389/fneur.2018.00701
Pedersen M, Verspoor K, Jenkinson M, et al. Artificial intelligence for clinical decision support in neurology. Brain Commun 2020; 2(2): fcaa096 doi: 10.1093/braincomms/fcaa096
